Sugi Predict

Sugi Predict / Compounds / SCHEMBL696315

SCHEMBL696315

SCHEMBL696315

CCOC(=O)C(=O)c1ccc(Br)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 5/20 0.57
▸ MAPT P10636 4/20 0.57
▸ MEN1 O00255 2/20 0.57
▸ S1PR4 O95977 1/20 0.57
▸ LMNA P02545 1/20 0.57
▸ S1PR1 P21453 1/20 0.57
▸ MAPK1 P28482 1/20 0.57
▸ NPSR1 Q6W5P4 1/20 0.57
▸ CES2 O00748 2/20 0.56
▸ CES1 P23141 2/20 0.56
▸ HTT P42858 2/20 0.51
▸ ALDH1A1 P00352 4/20 0.50
▸ HPGD P15428 2/20 0.49
▸ NHERF1 O14745 1/20 0.47
▸ FNTA P49354 1/20 0.46
▸ FNTB P49356 1/20 0.46
▸ SIRT2 Q8IXJ6 1/20 0.45
▸ RXFP1 Q9HBX9 1/20 0.45
▸ ACHE P22303 1/20 0.44
▸ GAA P10253 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11845871 0.95 MAPT (0.53) KMT2AMAPTMEN1S1PR4LMNA
SCHEMBL22257244 0.86 KMT2A (0.51) KMT2AMAPTMEN1S1PR4LMNA
SCHEMBL22257240 0.84 MAPT (0.62) KMT2AMAPTMEN1S1PR4LMNA
SCHEMBL21636244 0.84 MAPT (0.53) KMT2AMAPTMEN1LMNACES2
SCHEMBL167161 0.84 CES2 (0.60) KMT2AMAPTLMNAMAPK1CES2
SCHEMBL25375699 0.84 MAPT (0.43) KMT2AMAPTMEN1S1PR4LMNA
SCHEMBL4372776 0.83 HTT (0.55) KMT2AMAPTMEN1S1PR4LMNA
SCHEMBL4372774 0.83 HTT (0.55) KMT2AMAPTMEN1S1PR4LMNA
SCHEMBL13604742 0.83 HTT (0.55) KMT2AMAPTMEN1S1PR4LMNA
SCHEMBL641616 0.82 CA12 (0.66) KMT2AMAPTMEN1LMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260070874-A1 BENZOYLFORMIC ACID AMIDE DERIVATIVE KJ CHEMICALS CORPORATION (JP) 2026-03-12 — — US disclosed
EP-4651872-A1 COMPOUNDS, COMPOSITIONS AND METHODS OF USE TO TREAT HYPOPARATHYROIDISM AND OSTEOPOROSIS Septerna, Inc. (US) 2025-11-26 — — EP disclosed
EP-4610249-A1 BENZOYLFORMIC ACID AMIDE DERIVATIVE KJ Chemicals Corporation (JP) 2025-09-03 — — EP disclosed
CN-120152956-A Weed control method 先正达农作物保护股份公司 2025-06-13 — — CN disclosed
US-12291523-B2 LXR modulators with bicyclic core moiety ORSOBIO, INC. (US) 2025-05-06 — — US disclosed
CN-119053587-A 5- [7- (3, 4-Dihydro-1H-isoquinoline-2-carbonyl) -1,2,3,4 tetrahydroisoquinolin-6-yl ] -1H-pyrrole-3-carboxamide derivatives, pharmaceutical compositions containing same and use thereof as pro-apoptotic agents 法国施维雅药厂 2024-11-29 — — CN disclosed
WO-2024210074-A1 BENZOYLFORMIC ACID AMIDE DERIVATIVE ＫＪケミカルズ株式会社 2024-10-10 — — WO disclosed
US-20240317726-A1 NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY ORSOBIO, INC. 2024-09-26 — — US disclosed
WO-2024155601-A1 COMPOUNDS, COMPOSITIONS AND METHODS OF USE TO TREAT HYPOPARATHYROIDISM AND OSTEOPOROSIS SEPTERNA, INC. (US) 2024-07-25 — — WO disclosed
US-11970484-B2 LXR modulators with bicyclic core moiety ORSOBIO, INC. (US) 2024-04-30 — — US disclosed
EP-2051964-A2 FATTY ACID AMIDE HYDROLASE INHIBITORS University of Connecticut (US) 2009-04-29 — — EP disclosed
WO-2009052320-A1 METHODS AND COMPOUNDS FOR MODULATING CANNABINOID ACTIVITY NORTHEASTERN UNIVERSITY (US) 2009-04-23 — — WO disclosed
WO-2009052319-A1 MONOACYLGLYCEROL LIPASE INHIBITORS FOR MODULATION OF CANNABINOID ACTIVITY NORTHEASTERN UNIVERSITY (US) 2009-04-23 — — WO disclosed
WO-2009052319-A1 MONOACYLGLYCEROL LIPASE INHIBITORS FOR MODULATION OF CANNABINOID ACTIVITY NORTHEASTERN UNIVERSITY (US) 2009-04-23 — — WO disclosed
WO-2008013963-A2 FATTY ACID AMIDE HYDROLASE INHIBITORS UNIVERSITY OF CONNECTICUT (US) 2008-01-31 — — WO disclosed
WO-2008013963-A2 FATTY ACID AMIDE HYDROLASE INHIBITORS UNIVERSITY OF CONNECTICUT (US) 2008-01-31 — — WO disclosed
US-20060111353-A1 Substituted arylcyclopropylacetamides as glucokinase activators ELI LILLY AND COMPANY 2006-05-25 — — US disclosed
EP-1585739-A1 SUBSTITUTED ARYLCYCLOPROPYLACETAMIDES AS GLUCOKINASE ACTIVATORS ELI LILLY AND COMPANY (US) 2005-10-19 — — EP disclosed
WO-2004063179-A1 SUBSTITUTED ARYLCYCLOPROPYLACETAMIDES AS GLUCOKINASE ACTIVATORS ELI LILLY AND COMPANY (US) 2004-07-29 — — WO disclosed
US-6265436-B1 ANTIINFLAMMATORY AGENTS OXIS THERAPEUTICS INC. 2001-07-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240317726-A1 NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY NR1H2, NR1H3, NCOA3 KMT2A 1677/4885MAPT 4388/4885MEN1 4784/4885
US-12291523-B2 LXR modulators with bicyclic core moiety NR1H2, NR1H3, NR1H4 KMT2A 1470/4885MAPT 4396/4885MEN1 4655/4885
US-11970484-B2 LXR modulators with bicyclic core moiety NR1H2, NR1H3, NR1H4 KMT2A 1738/4885MAPT 4414/4885MEN1 4747/4885
US-20060111353-A1 Substituted arylcyclopropylacetamides as glucokinase activators GCK, GCKR, GALK1 KMT2A 1603/4885MAPT 4102/4885MEN1 4564/4885
US-20260070874-A1 BENZOYLFORMIC ACID AMIDE DERIVATIVE CRYAA, BCAT1, BRCA1 KMT2A 1265/4885MAPT 1426/4885MEN1 2820/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.